

# Europe Malaria Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Treatment Type (Antimalarial Agents, and Diagnostic Test); Route of Administration (Oral, and Parenteral); End User (Hospitals, Specialty Clinics, and Others)

Market Report | 2023-01-23 | 151 pages | The Insight Partners

### **AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

### Report description:

The Europe malaria treatment market is expected to grow from US\$ 593.03 million in 2022 to US\$ 785.75 million by 2028. It is estimated to register a CAGR of 4.8% from 2022 to 2028.

Extending Pipeline of New Drugs and Vaccines is Driving the Europe Malaria Treatment Market

Antimicrobial resistance threatens the public health response to many diseases, such as malaria, and the R&D of new medicines is the best strategy to overcome this challenge. With this, the antimalarial drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities in the malaria treatment market, creating lucrative opportunities for the market growth. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, is working with many pharmaceutical companies to reduce the burden of malaria by developing novel treatment options. In December 2019, Ipca Laboratories collaborated with MMV to develop Atoguanil, a novel antimalarial coformulation. So, extending pipeline of new drugs and vaccines is expected to drive the Europe malaria treatment market.

Europe Malaria Treatment Market Overview

The Europe malaria treatment market includes the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022. According to the European Center for Disease Prevention and Control report, in 2019, 8,641 malaria cases were registered in the European Union (EU), among which 8,638 (>99%) were malaria-confirmed cases.

**Scotts International. EU Vat number: PL 6772247784** tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Additionally, 5,509 cases (99.8%) of malaria cases were travel-related, among which two were registered in Germany. The cases in Germany were infected by vector-borne transmission. The EU supports eradicating malaria by aiming to facilitate the development and producing a highly efficacious malaria vaccine. For example, in July 2021, backed by the eradicate Malaria initiative, German company BioNTech announced a malaria project focusing on developing an mRNA-based vaccine against the disease and evaluating mRNA vaccine production in Africa. Moreover, in September 2022, Germany signed an agreement worth US\$ 1.34 billion with The Joint United Nations Programme on HIV/AIDS (UNAIDS), aiming to fight AIDS, tuberculosis, and malaria with an increase of 30% of the country's contribution from 2019. Further, from 2010 to 2020, international sources provided 69% of total funding aiming for malaria control and elimination, as per the endmalaria.org 2020 report. For example, total funding for malaria control and elimination accounted for US\$ 3.3 billion; Germany contributed US\$ 0.2 billion.

Europe Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)

Europe Malaria Treatment Market Segmentation

The Europe malaria treatment market is segmented based on treatment, drug type, route of administration, distribution channel, end user, and country.

Based on treatment, the Europe malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others. The diagnostic tests segment held the largest market share in 2022. The prescription medications segment is further categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.

Based on drug type, the Europe malaria treatment market is bifurcated into branded and generic. The generic segment held a larger market share in 2022.

Based on route of administration, the Europe malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held a larger market share in 2022.

Based on distribution channel, the Europe malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.

Based on end user, the Europe malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Europe malaria treatment market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany dominated the market in 2022.

AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, and Zydus Healthcare Ltd are among the leading companies operating in the Europe malaria treatment market.

### **Table of Contents:**

TABLE OF CONTENTS

- 1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 1.3 Market Segmentation
- 1.3.1 Europe Malaria Treatment Market By Treatment
- 1.3.2 Europe Malaria Treatment Market By Drug Type
- 1.3.3 Europe Malaria Treatment Market By Route of Administration
- 1.3.4 Europe Malaria Treatment Market By Distribution Channel
- 1.3.5 Europe Malaria Treatment Market By End User
- 1.3.6 Europe Malaria Treatment Market- By Country
- 2. Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. Europe Malaria Treatment Market- Market Landscape
- 4.1 Overview
- 4.2 Europe PEST Analysis
- 4.3 Experts Opinion
- 5. Europe Malaria Treatment Market Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Government and Private Sector's Initiatives to Raise Awareness About Malaria
- 5.2 Market Restraints
- 5.2.1 Counterfeit Antimalarial Drugs and Subsequent Drug Resistance
- 5.3 Market Opportunities
- 5.3.1 Extending Pipeline of New Drugs and Vaccines
- 5.4 Future Trends
- 5.4.1 Rapid Diagnostic Tests
- 5.5 Impact Analysis
- 6. Malaria Treatment Market- Europe Analysis
- 6.1 Europe Malaria Treatment Market Revenue Forecast and Analysis
- 7. Europe Malaria Treatment Market Analysis By Treatment
- 7.1 Overview
- 7.2 Europe Malaria Treatment Market, By Treatment 2021 & 2028 (%)
- 7.3 Prescription Medications
- 7.3.1 Overview
- 7.3.2 Prescription Medication Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.3.3 Chloroquine Phosphate
- 7.3.3.1 Overview
- 7.3.3.2 Chloroquine Phosphate Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.3.4 Artemisinin- based Combination Therapies (ACTs)
- 7.3.4.1 Overview
- 7.3.4.2 Artemisinin- based Combination Therapies (ACTs) Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.3.5 Atovaquone-Proguanil
- 7.3.5.1 Overview
- 7.3.5.2 Atovaguone-Proguanil Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.3.6 Quinine Sulphate (Qualaquin) with Doxycycline
- 7.3.6.1 Overview
- 7.3.6.2 Quinine Sulphate (Qualaquin) with Doxycycline Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.3.7 Primaquine Phosphate

### Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.7.1 Overview
- 7.3.7.2 Primaquine Phosphate Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.3.8 Others
- 7.3.8.1 Overview
- 7.3.8.2 Others Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.4 Vaccines
- 7.4.1 Overview
- 7.4.2 Vaccines Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.5 Diagnostic Tests
- 7.5.1 Overview
- 7.5.2 Diagnostic Tests Market Revenue and Forecast to 2028 (US\$ Mn)
- 7.6 Others
- 7.6.1 Overview
- 7.6.2 Others Market Revenue and Forecast to 2028 (US\$ Mn)
- 8. Europe Malaria Treatment Market Analysis By Drug Type
- 8.1 Overview
- 8.2 Europe Malaria Treatment Market, By Drug Type 2021 & 2028 (%)
- 8.3 Branded
- 8.3.1 Overview
- 8.3.2 Branded Market Revenue and Forecast to 2028 (US\$ Mn)
- 8.4 Generics
- 8.4.1 Overview
- 8.4.2 Generics Market Revenue and Forecast to 2028 (US\$ Mn)
- 9. Europe Malaria Treatment Market Analysis By Route of Administration
- 9 1 Overview
- 9.2 Europe Malaria Treatment Market, By Route of Administration 2021 & 2028 (%)
- 9.3 Oral
- 9.3.1 Overview
- 9.3.2 Oral Market Revenue and Forecast to 2028 (US\$ Mn)
- 9.4 Parenteral and Intravenous Mode
- 9.4.1 Overview
- 9.4.2 Parenteral and Intravenous Mode Market Revenue and Forecast to 2028 (US\$ Mn)
- 10. Europe Malaria Treatment Market Analysis By Distribution Channel
- 10.1 Overview
- 10.2 Europe Malaria Treatment Market, By Distribution Channel 2021 & 2028 (%)
- 10.3 Direct Tender
- 10.3.1 Overview
- 10.3.2 Direct Tender Market Revenue and Forecast to 2028 (US\$ Mn)
- 10.4 Hospital Pharmacies
- 10.4.1 Overview
- 10.4.2 Hospital Pharmacies Market Revenue and Forecast to 2028 (US\$ Mn)
- 10.5 Retail Pharmacies
- 10.5.1 Overview
- 10.5.2 Retail Pharmacies Market Revenue and Forecast to 2028 (US\$ Mn)
- 10.6 Online Pharmacies
- 10.6.1 Overview
- 10.6.2 Online Pharmacies Market Revenue and Forecast to 2028 (US\$ Mn)

### Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 10.7 Others
- 10.7.1 Overview
- 10.7.2 Others Market Revenue and Forecast to 2028 (US\$ Mn)
- 11. Europe Malaria Treatment Market Analysis By End User
- 11.1 Overview
- 11.2 Europe Malaria Treatment Market, By End User 2021 & 2028 (%)
- 11.3 Hospitals
- 11.3.1 Overview
- 11.3.2 Hospitals Market Revenue and Forecast to 2028 (US\$ Mn)
- 11.4 Specialty Clinics
- 11.4.1 Overview
- 11.4.2 Specialty Clinics Market Revenue and Forecast to 2028 (US\$ Mn)
- 11.5 Homecare
- 11.5.1 Overview
- 11.5.2 Homecare Market Revenue and Forecast to 2028 (US\$ Mn)
- 11.6 Others
- 11.6.1 Overview
- 11.6.2 Others Market Revenue and Forecast to 2028 (US\$ Mn)
- 12. Europe Malaria Treatment Market Country Analysis
- 12.1 Overview
- 12.1.2 Europe: Malaria Treatment Market, by Country, 2021 & 2028 (%)
- 12.1.2.1 Germany: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.1.1 Overview
- 12.1.2.1.2 Germany: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.1.3 Germany: Malaria Treatment Market, by Treatment Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.1.3.1 Germany: Malaria Treatment Market, by Prescription Medication, 2020-2028 (US\$ Million)
- 12.1.2.1.4 Germany: Malaria Treatment Market, by Drug Type- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.1.5 Germany: Malaria Treatment Market, by Route of Administration Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.1.6 Germany: Malaria Treatment Market, by Distribution Channel Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.1.7 Germany: Malaria Treatment Market, by End User Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.2 France: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.2.1 Overview
- 12.1.2.2.2 France: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.2.3 France: Malaria Treatment Market, by Treatment Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.2.3.1 France: Malaria Treatment Market, by Prescription Medication, 2020-2028 (US\$ Million)
- 12.1.2.2.4 France: Malaria Treatment Market, by Drug Type- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.2.5 France: Malaria Treatment Market, by Route of Administration- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.2.6 France: Malaria Treatment Market, by Distribution Channel Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.2.7 France: Malaria Treatment Market, by End User Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.3 UK: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.3.1 Overview
- 12.1.2.3.2 UK: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.3.3 UK: Malaria Treatment Market, by Treatment Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.3.3.1 UK: Malaria Treatment Market, by Prescription Medication, 2020-2028 (US\$ Million)
- 12.1.2.3.4 UK: Malaria Treatment Market, by Drug Type- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.3.5 UK: Malaria Treatment Market, by Route of Administration- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.3.6 UK: Malaria Treatment Market, by Distribution Channel Revenue and Forecast to 2028 (US\$ Million)

- 12.1.2.3.7 UK: Malaria Treatment Market, by End User Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.4 Italy: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.4.1 Overview
- 12.1.2.4.2 Italy: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.4.3 Italy: Malaria Treatment Market, by Treatment Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.4.3.1 Italy: Malaria Treatment Market, by Prescription Medication, 2020-2028 (US\$ Million)
- 12.1.2.4.4 Italy: Malaria Treatment Market, by Drug Type- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.4.5 Italy: Malaria Treatment Market, by Route of Administration- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.4.6 Italy: Malaria Treatment Market, by Distribution Channel Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.4.7 Italy: Malaria Treatment Market, by End User Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.5 Spain: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.5.1 Overview
- 12.1.2.5.2 Spain: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.5.3 Spain: Malaria Treatment Market, by Treatment Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.5.3.1 Spain: Malaria Treatment Market, by Prescription Medication, 2020-2028 (US\$ Million)
- 12.1.2.5.4 Spain: Malaria Treatment Market, by Drug Type- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.5.5 Spain: Malaria Treatment Market, by Route of Administration- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.5.6 Spain: Malaria Treatment Market, by Distribution Channel Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.5.7 Spain: Malaria Treatment Market, by End User Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.6 Rest of Europe: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.6.1 Overview
- 12.1.2.6.2 Rest of Europe: Malaria Treatment Market Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.6.3 Rest of Europe: Malaria Treatment Market, by Treatment Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.6.3.1 Rest of Europe: Malaria Treatment Market, by Prescription Medication, 2020-2028 (US\$ Million)
- 12.1.2.6.4 Rest of Europe: Malaria Treatment Market, by Drug Type- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.6.5 Rest of Europe: Malaria Treatment Market, by Route of Administration- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.6.6 Rest of Europe: Malaria Treatment Market, by Distribution Channel Revenue and Forecast to 2028 (US\$ Million)
- 12.1.2.6.7 Rest of Europe: Malaria Treatment Market, by End User Revenue and Forecast to 2028 (US\$ Million)
- 13. Industry Landscape
- 13.1 Overview
- 13.2 Inorganic Growth Strategies
- 13.2.1 Overview
- 13.3 Organic Growth Strategies
- 13.3.1 Overview
- 14. Company Profiles
- 14.1 Zydus Healthcare Ltd
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
- 14.2 Sun Pharmaceutical Industries Ltd
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
- 14.4 GSK Plc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 Novartis AG
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 Cipla Ltd
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 Viatris Inc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
- 14.8 Lupin Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 AdvaCare Pharma USA LLC
- 14.9.1 Key Facts
- 14.9.2 Business Description

## Scotts International. EU Vat number: PL 6772247784

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

Scotts International. EU Vat number: PL 6772247784



To place an Order with Scotts International:

Print this form

# Europe Malaria Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Treatment Type (Antimalarial Agents, and Diagnostic Test); Route of Administration (Oral, and Parenteral); End User (Hospitals, Specialty Clinics, and Others)

Market Report | 2023-01-23 | 151 pages | The Insight Partners

□ - Complete the re	elevant blank fields and sign			
- Send as a scan	ned email to support@scotts-inte	rnational.com		
ORDER FORM:				
Select license	License			Price
	Single User Price			\$3000.00
	Site Price			\$4000.00
	Enterprise Price			\$5000.00
			VAT	
			Total	
Email*	is 25/0 for 1 only 1 dased companies, in	Phone*	companies who are unable to provide a	
l		<b>」</b> ¬		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID	/ NIP number*	
Address*		City*		
Zip Code*		Country*		

Scotts International. EU Vat number: PL 6772247784

Date	2025-05-05	
Signature		